Table 1.
The demographic and clinical information of 130 PEMa patients
| Variable | Patients number | Mean ± SDb, Median (IQRc) or Percentage |
|---|---|---|
| Demographic data | ||
| Age at surgery, yr | 130 | 33.40 ± 4.55 |
| Height, cm | ||
| Weight, kg | ||
| BMId, kg/m2 | 130 | 21.80 (20.15–23.75) |
| Gravidy | 130 | 2 (1–2) |
| Parity | 130 | 1 (1–1) |
| Age at delivery, yr | 129 | 26.45 ± 3.45 |
| Age at onset of symptoms | ||
| Repeated surgery for PEM | 28/130 | 21.5% |
| Clinical data | ||
| Pathogenesis | ||
| Spontaneous | 1/130 | 0.8% |
| Episiotomy | 99/130 | 76.2% |
| Obstetrical lacerations | 29/130 | 22.3% |
| Episiotomy & Obstetrical laceration | 1/130 | 0.8% |
| Latent period, mo | 119 | 36.00 (12.00–54.00) |
| Duration of symptoms, mo | 130 | 36.00 (24.00–48.00) |
| CAe 125, IU/L | 100 | 22.15 (14.38–33.46) |
| CA 125 ≥ 35 IU/L | 20/100 | 20.0% |
| Dysmenorrhea | 33/130 | 25.4% |
| Coexistent OEMf | 15/130 | 11.5% |
| Coexistent AMg | 18/130 | 13.8% |
| Preoperative GnRH-ah | 78/130 | 60.0% |
| Surgical and pathological data | ||
| Multiple lesions | 32/130 | 24.6% |
| Size of lesions, cm | 130 | 2.50 (2.00–3.00) |
| Size of lesions ≥ 3 cm | 55/130 | 42.3% |
| Anal sphincter involvement by pathology | 43/130 | 33.1% |
| Positive cut edge | 37/120 | 30.8% |
| Location of the lesion | ||
| Middle | 19/120 | 15.8% |
| Left side | 92/120 | 76.7% |
| Right side | 9/120 | 7.5% |
| Postoperative data | ||
| Postoperative complications | 17/130 | 13.1% |
| Delayed healing | 12/130 | 9.2% |
| Wound infection | 2/130 | 1.5% |
| Fistula | 2/130 | 1.5% |
| Uroschesis | 1/130 | 0.8% |
| Hospitalization days | 126 | 9 (7–12) |
| Postsurgical medication | ||
| None | 70/130 | 53.8% |
| GnRH-a | 36/130 | 27.7% |
| Progestogen | 13/130 | 10.0% |
| COCsi | 11/130 | 8.5% |
| Recurrence | 16/104 | 13.3% |
aPEM perineal endometriosis; bSD standard deviation; cIQR interquartile range; dBMI body mass index; eCA-125 cancer antigen 125; fOEM ovarian endometriosis; gAM adenomyosis; hGnRH-a gonadotrophin releasing hormone agonist; iCOCs combined oral contraceptives